Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY(TM) (Romosozumab) In Postmenopausal Women With Osteoporosis

ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures Imbalance in Cardiovascular Events Observed as New Safety Signal THOUSAND OAKS, Calif. and BRUSSELS, May 21, 2017 -- (... Biopharmaceuticals Amgen, UCB , romosozumab, EVENITY, osteoporosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news